BDSX.US Biodesix Inc

Healthcare Biotechnology USA Stocks
9.88 USD
Close of Nov 14, 2026
5.26 31.97
Market cap
USD 110M
P/E
-
P/B
12.57x
ROE
-355.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is BDSX.US undervalued?

Graham number

The Graham number of Biodesix Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biodesix Inc fundamental analysis

No fundamental analysis for Biodesix Inc yet.

Biodesix Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biodesix Inc

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQL…

Full company profile